R

Retina Group of New England | Waterford, CT

Research site
(Unclaimed)
Location
174 Cross Road, Waterford, Connecticut, United States of America
Site insights

Top conditions

Macular Degeneration (9 trials)

Macular Edema (7 trials)

Edema (7 trials)

Wet Macular Degeneration (5 trials)

Retinal Vein Occlusion (3 trials)

Top treatments

Ranibizumab
KSI-301
Aflibercept
Faricimab
ABP 938
APL-2
RG7774
Lampalizumab
Eylea®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 19
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

This study will assess corneal endothelial cells in patients with neovascular age-related macular degeneration (nAMD) treated with Port Delivery Syst...

Enrolling
Neovascular Age-related Macular Degeneration
Drug: LUCENTIS (ranibizumab injection)
Device: SUSVIMO Port Delivery System with ranibizumab (PDS)

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Trial sponsors

Roche logo

Roche (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems